Respiratory Tract

Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Respiratory Tract Resource Center

Welcome to the MPR Respiratory Tract Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

News

ATS: Effects of Prenatal Pollution Exposure Persist

Maternal pollutant exposure has lasting effect on lung function development in children with asthma

ATS: Sleep Apnea Tied to Increased Risk of Cancer Death

Obstructive sleep apnea (OSA) is associated with an increased risk of cancer mortality.

Phase 3 Trial Update of NVA237 for COPD

Sosei Group Corporation confirmed the information released today by Novartis that results from the pivotal Phase 3 GLOW2 study demonstrated that once-daily 50mcg NVA237 (glycopyrronium bromide) was superior to placebo in improving lung function, symptom relief and quality of life, and reducing exacerbations over a one-year period in patients with chronic obstructive pulmonary disease (COPD).

Outcomes Good for Status Asthmaticus Patients in ICU

Although the majority of patients admitted to the intensive care unit (ICU) with status asthmaticus (SA) require mechanical ventilation, the rates of mortality and complications are very low.

Small Benefit of Inhaled Corticosteroids for Sinusitis

For patients with acute sinusitis, inhaled corticosteroids provide a small benefit over placebo but only after several weeks.

QNASL

4/30/2012

Teva Pharmaceuticals

Pharmacological Class: Steroid.

Active Ingredient(s): Beclomethasone dipropionate 80mcg/actuation; non-aqueous nasal spray soln.

Indication: Seasonal and perennial allergic rhinitis.

ARCAPTA NEOHALER

4/16/2012

Novartis Pharmaceuticals Corp

Pharmacological Class: Long-acting beta₂-agonist (LABA).

Active Ingredient(s): Indacaterol 75mcg; inhalation pwd hard capsules for use with Neohaler device.

Indication: Long-term maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and/or emphysema.

DALIRESP

6/16/2011

Forest Laboratories

Pharmacological Class: Selective phosphodiesterase 4 (PDE4) inhibitor

Active Ingredient(s): Roflumilast 500mcg; tabs.

Indication: To reduce risk of COPD exacerbations in severe COPD patients with chronic bronchitis and a history of exacerbations. Not for the relief of acute bronchospasm.